Supplementary Figure 1. Individual direct meta-analysis of SBP risk

A. Direct meta-analysis (risk difference) (Ciprofloxacin vs. Placebo)



B. Direct meta-analysis (risk difference) (Norfloxacin vs. Placebo)



C. Direct meta-analysis (risk difference) (Trimethoprim/sulfamethoxazole vs. Placebo)



D. Direct meta-analysis (risk difference) (Rifaximin vs. Norfloxacin)



E. Direct meta-analysis (risk difference) (Trimethoprim/sulfamethoxazole vs. Norfloxacin)



F. Direct meta-analysis (risk difference) (Ciprofloxacin vs. Norfloxacin)



Supplementary Figure 2. Network meta-analysis excluding studies with Jadad score ≤2

A. Network of treatment comparisons



B. Relative effects of between each treatment

CPFX	1.24 (0.17, 7.62)	4.70 (0.79, 38.10)	0.42 (0.03, 4.36)	1.21 (0.03, 36.04)
0.81 (0.13, 5.90)	NFX	3.91 (1.47, 16.44)	0.35 (0.07, 1.56)	0.97 (0.05, 17.98)
0.21 (0.03, 1.27)	0.26 (0.06, 0.68)	Placebo	0.09 (0.01, 0.49)	0.25 (0.01, 4.94)
2.39 (0.23, 30.89)	2.89 (0.64, 15.00)	11.03 (2.02, 114.71)	RFX	2.81 (0.11, 82.88)
0.83 (0.03, 28.60)	1.03 (0.06, 20.21)	3.95 (0.20, 111.32)	0.36 (0.01, 9.39)	TMPSMX

C. Rank probability (Consistency model) (No. 5 is the best)



Drug	Rank 1	Rank 2	Rank 3	Rank 4	Rank 5	SUCRA	95% CI		SUCRA Rank
CPFX	0.03	0.24	0.27	0.31	0.15	0.58	0.23	0.92	2
NFX	0	0.29	0.48	0.22	0.01	0.49	0.047	0.93	4
Placebo	0.80	0.18	0.01	0	0	0.050	-0.042	0.14	5
RFX	0.01	0.02	0.07	0.27	0.63	0.87	0.71	1.04	1
TMPSMX	0.16	0.26	0.17	0.20	0.21	0.51	0.25	0.77	3

Supplementary Figure 3. Network meta-analysis of SBP risk for primary prophylaxis

A. Network of treatment comparisons



B. Relative effects of between each treatment

CPFX	0.26 (0.01, 11.72)	3.98 (0.20, 113.45)	0.12 (0.00, 13.08)
3.83 (0.09, 162.12)	NFX	14.05 (2.33, 180.15)	0.48 (0.02, 9.17)
0.25 (0.01, 4.97)	0.07 (0.01, 0.43)	Placebo	0.03 (0.00, 0.81)
8.01 (0.08, 1025.14)	2.10 (0.11, 41.79)	29.77 (1.24, 1658.21)	RFX

C. Rank probability (Consistency model) (No. 4 is the best)



Drug	Rank 1	Rank 2	Rank 3	Rank 4	SUCRA	95% CI		SUCRA Rank
CPFX	0.12	0.62	0.13	0.12	0.41	0.021	0.81	3
NFX	0	0.17	0.66	0.17	0.67	0.24	1.10	2
Placebo	0.86	0.14	0.01	0	0.05	-0.029	0.14	4
RFX	0.02	0.08	0.19	0.71	0.86	0.73	1.00	1

Supplementary Figure 4. Network meta-analysis of SBP risk for secondary prophylaxis

A. Network of treatment comparisons



B. Relative effects of between each treatment

CPFX	1.44 (0.05, 42.24)	4.84 (0.12, 285.50)	0.15 (0.00, 6.53)	1.23 (0.02, 61.58)
0.69 (0.02, 18.94)	NFX	3.34 (0.58, 25.88)	0.10 (0.00, 0.78)	0.85 (0.10, 6.34)
0.21 (0.00, 8.42)	0.30 (0.04, 1.73)	Placebo	0.03 (0.00, 0.37)	0.25 (0.02, 2.24)
6.88 (0.15, 835.66)	9.59 (1.29, 273.52)	32.99 (2.67, 1918.91)	RFX	8.13 (0.48, 428.84)
0.81 (0.02, 45.60)	1.17 (0.16, 10.05)	3.97 (0.45, 56.18)	0.12 (0.00, 2.07)	TMPSMX

C. Rank probability (Consistency model) (No. 4 is the best)



Drug	Rank 1	Rank 2	Rank 3	Rank 4	Rank 5	SUCRA	95% CI		Rank
CPFX	0.14	0.19	0.17	0.38	0.12	0.54	0.23	0.85	2
NFX	0.02	0.35	0.46	0.16	0.00	0.44	0.0046	0.87	4
Placebo	0.78	0.17	0.04	0.02	0.00	0.078	-0.025	0.18	5
RFX	0.00	0.01	0.02	0.13	0.84	0.95	0.88	1.02	1
TMPSMX	0.06	0.28	0.30	0.31	0.04	0.49	0.12	0.87	3

Supplementary Figure 5. Network meta-analysis of SBP risk among studies published after 2010

A. Network of treatment comparisons



B. Relative effects of between each treatment

CPFX	1.42 (0.03, 63.25)	2.61 (0.01, 497.16)	0.29 (0.00, 17.02)	1.51 (0.01, 399.37)
0.71 (0.02, 35.90)	NFX	1.79 (0.04, 76.51)	0.20 (0.01, 1.25)	0.98 (0.02, 55.01)
0.38 (0.00, 90.74)	0.56 (0.01, 23.64)	Placebo	0.11 (0.00, 5.59)	0.55 (0.00, 119.43)
3.45 (0.06, 494.85)	4.97 (0.80, 82.08)	8.75 (0.18, 1028.99)	RFX	5.13 (0.07, 702.71)
0.66 (0.00, 189.87)	1.02 (0.02, 54.37)	1.81 (0.01, 411.01)	0.19 (0.00, 13.95)	TMPSMX

C. Rank probability (Consistency model) (No. 4 is the best)



Drug	Rank 1	Rank 2	Rank 3	Rank 4	Rank 5	SUCRA	95% CI		SUCRA Rank
CPFX	0.14	0.19	0.17	0.38	0.12	0.54	0.23	0.85	2
NFX	0.02	0.35	0.46	0.16	0.00	0.44	0.0046	0.87	4
Placebo	0.78	0.17	0.04	0.02	0.00	0.078	-0.025	0.18	5
RFX	0.00	0.01	0.02	0.13	0.84	0.95	0.88	1.02	1
TMPSMX	0.06	0.28	0.30	0.31	0.04	0.49	0.12	0.87	3

Supplementary Figure 6. Individual direct meta-analysis of death/transplant risk

A. Direct meta-analysis (risk difference) (Ciprofloxacin vs. Placebo)



B. Direct meta-analysis (risk difference) (Norfloxacin vs. Placebo)



C. Direct meta-analysis (risk difference) (Trimethoprim/sulfamethoxazole vs. Placebo)



D. Direct meta-analysis (risk difference) (Rifaximin vs. Norfloxacin)



E. Direct meta-analysis (risk difference) (Trimethoprim/sulfamethoxazole vs. Norfloxacin)



F. Direct meta-analysis (risk difference) (Ciprofloxacin vs. Norfloxacin)